Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution.
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Carteolol/latanoprost (Primary) ; Latanoprost
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Therapeutic Use
- 22 Feb 2017 New trial record